Salvage Docetaxel for Pretreated Urothelial Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Based on the previous clinical experience in other cancers, and considering the absence of
current standard salvage regimens, the single agent docetaxel is selected as the regimen for
this phase II study. Main toxicity of docetaxel is myelosuppression. The low rate of severe
myelosuppression observed in other cancer trials warrants further study in urothelial cancer.
The objective of the study is to evaluate the safety and activity of weekly docetaxel given
as salvage therapy for advanced urothelial cancer.